Literature DB >> 34090700

Does influenza vaccination attenuate the severity of breakthrough infections? A narrative review and recommendations for further research.

Jill M Ferdinands1, Mark G Thompson2, Lenee Blanton3, Sarah Spencer3, Lauren Grant3, Alicia M Fry3.   

Abstract

The effect of influenza vaccination on influenza severity remains uncertain. We reviewed the literature for evidence to inform the question of whether influenza illness is less severe among individuals who received influenza vaccination compared with individuals with influenza illness who were unvaccinated prior to their illnesses. We conducted a narrative review to identify published findings comparing severity of influenza outcomes by vaccination status among community-dwelling adults and children ≥ 6 months of age with laboratory-confirmed influenza illness. When at least four effect estimates of the same type (e.g., odds ratio) were available for a specific outcome and age category (children versus adults), data were pooled with meta-analysis to generate a summary effect estimate. We identified 38 published articles reporting ≥ 1 association between influenza vaccination status and one of 21 indicators of severity of influenza illness among individuals with laboratory-confirmed influenza. Study methodologies and effect estimates were highly heterogenous, with only five severity indicators meeting criteria for calculating a combined effect. Among eight studies, influenza vaccination was associated with 26% reduction in odds of ICU admission among adults with influenza-associated hospitalization (OR = 0.74, 95% CI 0.58, 0.93). Among five studies of adults with influenza-associated hospitalization, vaccinated patients had 31% reduced risk of death compared with unvaccinated patients (OR = 0.69, 95% CI 0.52, 0.92). Among four studies of children with influenza virus infection, vaccination was associated with an estimated 45% reduction in the odds of manifesting fever (OR = 0.55, 95% CI 0.42, 0.71). Vaccination was not significantly associated with receiving a clinical diagnosis of pneumonia among adults hospitalized with influenza (OR = 0.92, 95% CI 0.82, 1.04) or with risk of hospitalization following outpatient influenza illness among adults (OR = 0.60, 95% CI 0.28, 1.28). Overall, our findings support the hypothesis that influenza vaccination may attenuate the course of disease among individuals with breakthrough influenza virus infection. Published by Elsevier Ltd.

Entities:  

Keywords:  Influenza; Severity; Vaccination; Vaccine effectiveness

Year:  2021        PMID: 34090700     DOI: 10.1016/j.vaccine.2021.05.011

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  11 in total

Review 1.  A literature review of severity scores for adults with influenza or community-acquired pneumonia - implications for influenza vaccines and therapeutics.

Authors:  Katherine Adams; Mark W Tenforde; Shreya Chodisetty; Benjamin Lee; Eric J Chow; Wesley H Self; Manish M Patel
Journal:  Hum Vaccin Immunother       Date:  2021-11-10       Impact factor: 3.452

2.  Antigenic and virological properties of an H3N2 variant that continues to dominate the 2021-22 Northern Hemisphere influenza season.

Authors:  Marcus J Bolton; Jordan T Ort; Ryan McBride; Nicholas J Swanson; Jo Wilson; Moses Awofolaju; Colleen Furey; Allison R Greenplate; Elizabeth M Drapeau; Andrew Pekosz; James C Paulson; Scott E Hensley
Journal:  Cell Rep       Date:  2022-05-31       Impact factor: 9.995

3.  The magnitude and timing of recalled immunity after breakthrough infection is shaped by SARS-CoV-2 variants.

Authors:  Marios Koutsakos; Wen Shi Lee; Arnold Reynaldi; Hyon-Xhi Tan; Grace Gare; Paul Kinsella; Kwee Chin Liew; George Taiaroa; Deborah A Williamson; Helen E Kent; Eva Stadler; Deborah Cromer; David S Khoury; Adam K Wheatley; Jennifer A Juno; Miles P Davenport; Stephen J Kent
Journal:  Immunity       Date:  2022-05-27       Impact factor: 43.474

4.  Post-vaccination outcomes in association with four COVID-19 vaccines in the Kingdom of Bahrain.

Authors:  Manaf AlQahtani; Xing Du; Sujoy Bhattacharyya; Abdulla Alawadi; Hamad Al Mahmeed; Jaleela Al Sayed; Jessica Justman; Wafaa M El-Sadr; Jack Hidary; Siddhartha Mukherjee
Journal:  Sci Rep       Date:  2022-06-02       Impact factor: 4.996

5.  Identification of groups at high risk for under-coverage of seasonal influenza vaccination: A national study to inform vaccination priorities during the COVID-19 pandemic.

Authors:  Kushagra Vashist; Deasung Choi; Shivani A Patel
Journal:  Ann Epidemiol       Date:  2021-12-17       Impact factor: 3.797

6.  Comparison of severity of immunized versus non-immunized COVID-19 patients admitted to ICU: A prospective observational study.

Authors:  Huda Mhawish; Ahmed Mady; Faisal Alaklobi; Waleed Aletreby; Tasmiya Asad; Mohammed Alodat; Abdulrahman Alharthy; Basheer Abdulrahman; Saleh Almahwi; Ziad A Memish
Journal:  Ann Med Surg (Lond)       Date:  2021-10-15

7.  Influenza A(H3N2) Outbreak on a University Campus - Michigan, October-November 2021.

Authors:  Miranda J Delahoy; Lindsey Mortenson; Laura Bauman; Juan Marquez; Natasha Bagdasarian; Joseph Coyle; Kelsey Sumner; Nathaniel M Lewis; Adam S Lauring; Brendan Flannery; Manish M Patel; Emily T Martin
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2021-12-10       Impact factor: 17.586

8.  An In Vitro Microneutralization Assay for Influenza Virus Serology.

Authors:  Frans Cuevas; Hisaaki Kawabata; Florian Krammer; Juan Manuel Carreño
Journal:  Curr Protoc       Date:  2022-07

Review 9.  Influenza.

Authors:  Timothy M Uyeki; David S Hui; Maria Zambon; David E Wentworth; Arnold S Monto
Journal:  Lancet       Date:  2022-08-27       Impact factor: 202.731

10.  Efficacy of Naproxen/Fexofenadine (SJP-003) in the Prevention of Side Effects of Influenza Vaccination: Four Case Studies.

Authors:  Pantea Kiani; Thomas A Dahl; Jacqueline M Iversen; Andrew Scholey; Joris C Verster
Journal:  Clin Pract       Date:  2022-09-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.